Exagen Inc. Partners with Sonora Quest Laboratories to Offer AVISE Testing for Patients Suspected of Autoimmune Disease
March 16 2020 - 8:19AM
Exagen Inc. (Nasdaq: XGN), an organization dedicated to
transforming the care continuum for patients suffering from
debilitating and chronic autoimmune diseases by enabling timely
differential diagnosis and optimizing therapeutic intervention,
today announced that it has entered into a strategic partnership
with Sonora Quest, the nation’s largest integrated laboratory
system. The agreement provides preferred access through Sonora
Quest in Arizona to Exagen’s AVISE testing. The testing can
facilitate improved care through the differential diagnosis,
prognosis, monitoring and therapeutic optimization of complex and
incurable autoimmune rheumatic diseases. The details of the
agreement are confidential.
“We’re pleased to be working with Sonora Quest in a shared
commitment to improve patients’ lives. Expanding access to our
portfolio of innovative products will have a significant impact on
patients, enabling rheumatologists to improve patient care through
insights available exclusively through our patented technology,”
said Ron Rocca, President and CEO of Exagen. “This is an important
step towards helping the estimated 23 million Americans who are yet
to be accurately diagnosed for conditions that can present with
symptoms similar to lupus or rheumatoid arthritis.”
“The AVISE tests add tremendous value to our continually
expanding menu of testing, providing consumers in Arizona more
power to proactively manage their health through access to
innovative testing platforms,” said Christina Noble, Chief Growth
Officer at Sonora Quest Laboratories. “Lupus is known for being
difficult to diagnose because its symptoms differ from person to
person, mimic the symptoms of many other diseases, and can come and
go. A Lupus Foundation of America survey found that on average, it
takes nearly six years for people with lupus to be diagnosed, and
this partnership seeks to reduce that delay.”
AVISE testing will be available through healthcare provider
customers of Sonora Quest beginning in spring 2020. Healthcare
providers and patients and their families can find more information
about this testing at www.avisetest.com and can expect to see
additional information on www.SonoraQuest.com in the coming
weeks.
About Autoimmune Rheumatic Diseases
Autoimmune rheumatic diseases are a diverse group of conditions
that primarily impact the joints, bones, muscle and connective
tissue. Patients with these autoimmune diseases often suffer
debilitating symptoms such as pain, depression and fatigue leading
to reduced quality of life and loss of productivity. Diagnosing
these conditions early is difficult and there is no known cause nor
cure. Women are disproportionately affected by autoimmune rheumatic
diseases and in lupus, for example, more than 85 percent of
patients are female.
About Exagen Inc.
Exagen is dedicated to transforming the care continuum for
patients suffering from debilitating and chronic autoimmune
diseases by enabling timely differential diagnosis and optimizing
therapeutic intervention. Exagen has developed and is
commercializing a portfolio of innovative testing products under
its AVISE brand, several of which are based on its proprietary
Cell-Bound Complement Activation Products (CB-CAPs) technology.
Exagen’s goal is to enable rheumatologists to improve care for
patients through the differential diagnosis, prognosis and
monitoring of complex autoimmune and autoimmune-related diseases,
including SLE and rheumatoid arthritis. For further information
please visit www.exagen.com.
About Sonora Quest Laboratories
Sonora Quest Laboratories, a joint venture between Banner Health
and Quest Diagnostics (NYSE: DGX), is part of the nation’s largest
integrated laboratory system with approximately 3,500 employees
serving more than 22,000 patients every day throughout Arizona.
Sonora Quest Laboratories is the market share leader in clinical
laboratory testing in Arizona, performing nearly 90 million
diagnostic tests per year.
Forward Looking Statements
Exagen cautions you that statements in this press release that
are not a description of historical facts are forward-looking
statements. These statements are based on the Company's current
beliefs and expectations. Such forward-looking statements include,
but are not limited to, statements regarding availability of AVISE
testing through Sonora Quest, and any potential for increased use
of AVISE laboratory tests. The inclusion of forward-looking
statements should not be regarded as a representation by Exagen
that any of its plans will be achieved. Actual results may differ
from those set forth in this press release due to the risks and
uncertainties inherent in Exagen’s business, including, without
limitation: Exagen’s commercial success depends upon attaining and
maintaining significant market acceptance of its testing products
and promoted therapeutics among rheumatologists, patients,
third-party payers and others in the medical community; risks
associated with maintaining third-party collaborations such as
consulting
advisors and Exagen’s performance thereunder; and other risks
described in the Company’s prior press releases and in the
Company’s filings with the Securities and Exchange Commission,
including under the heading "Risk Factors" in the Company’s
Registration Statement on Form S-1 and any subsequent filings with
the SEC. You are cautioned not to place undue reliance on these
forward-looking statements, which speak only as of the date hereof,
and we undertake no obligation to revise or update this press
release to reflect events or circumstances after the date hereof.
All forward-looking statements are qualified in their entirety by
this cautionary statement, which is made under the safe harbor
provisions of the Private Securities Litigation Reform Act of
1995.
Brian McEvilly (Company)
Exagen Inc.
760.560.1506
bmcevilly@exagen.com
Alexander Petti (Media)
Evoke KYNE
646.831.0955
alexander.petti@evokegroup.com
Mike Cavanaugh (Investors)
Westwicke Partners
646.677.1838
Mike.Cavanaugh@westwicke.com
Exagen (NASDAQ:XGN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Exagen (NASDAQ:XGN)
Historical Stock Chart
From Apr 2023 to Apr 2024